5-Amino 1MQ + NADH

5-Amino-1MQ + NADH Research Blend is a combination research preparation containing two distinct metabolism-modulating compounds: 5-Amino-1-methylquinolinium (5-Amino-1MQ), a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), supplied at 50 mg/mL, combined with NADH (the reduced form of nicotinamide adenine dinucleotide), supplied at 40 mg/mL, in a 20 mL liquid vehicle. This combination format is used in research contexts where investigators wish to study the joint effects of NNMT inhibition (which elevates the intracellular NAD+ precursor pool by slowing N-methylation of nicotinamide) alongside direct NADH supplementation in the same experimental system.

5-Amino-1MQ mechanism: NNMT methylates nicotinamide (a NAD+ breakdown product) to 1-methylnicotinamide, diverting it from the NAD+ salvage pathway and depleting the usable NAD+ precursor pool. Inhibiting NNMT with 5-Amino-1MQ has been investigated in the context of adipose tissue metabolism, tumor microenvironment remodeling, and gut microbiome composition in preclinical models.

Potential Research Applications: NNMT inhibition research in adipocyte and metabolic-tissue models (obesogenic diet conditions) Tumor microenvironment and cancer-associated fibroblast (CAF) NAD+ metabolism studies NAD+/NADH ratio manipulation experiments in metabolic disease research models Gut microbiome composition studies in combination metabolic intervention models

What the Published NNMT-Inhibitor Work Supports

The methylquinolinium scaffold that 5-Amino-1MQ belongs to was characterized in a 2018 Biochemical Pharmacology study of selective, membrane-permeable NNMT inhibitors. In that work the primary-amine-substituted methylquinolinium analogs showed high passive and active membrane permeability, did not inhibit related SAM-dependent methyltransferases or NAD+ salvage enzymes, reduced intracellular 1-methylnicotinamide, raised intracellular NAD+ and SAM, and suppressed lipogenesis in cultured adipocytes. Systemic treatment of diet-induced obese mice with a potent inhibitor from the series reduced body weight, white adipose mass, adipocyte size, and plasma total cholesterol without changing food intake. A 2022 Scientific Reports follow-up used 5-amino-1-methylquinolinium specifically, combined with a low-fat diet switch, and reported that the cecal microbiome of treated diet-induced obese mice moved toward that of age-matched lean animals. Separately, NNMT expression in cancer-associated fibroblasts has been linked to tumor progression and immunotherapy resistance in urothelial bladder cancer, which is why the enzyme is also studied outside metabolism.

None of this work used an NNMT inhibitor co-formulated with NADH. The rationale for pairing the two in one vial is mechanistic (raise NAD+ precursor availability while supplying reduced cofactor directly), not something a published study has tested as a combination. Researchers should treat the blend as two independent variables and run single-agent arms.

Why NADH Is the Less Stable Half of the Blend

NADH is the reduced form of the coenzyme and is far more sensitive to acidic pH, light, and oxidation than NAD+. In a 20 mL liquid co-formulation, the NADH component will degrade faster than the small-molecule inhibitor, so the effective NADH:5-Amino-1MQ ratio drifts with storage time. The broader NAD+ metabolism literature summarized in a 2021 Nature Reviews Molecular Cell Biology review documents the age-related decline in tissue NAD+ and its links to metabolic disease, which is the context most investigators are working in when they reach for this combination.

Live Market Data on Peptides.SO (listing data on file as of 13 September 2026)

Peptides.SO currently tracks 1 listing for the 5-Amino-1MQ + NADH blend, from Nextech Labs at $89.99 (priced per mg on the listing for the combined liquid formulation). The median list price across the 595 priced listings in the platform's weight-management category is $75.00, placing this blend about 20% above the category midpoint. For a single-agent comparison, the standalone 5-Amino-1MQ page aggregates every supplier carrying the inhibitor alone, and the NAD+ page does the same for the oxidized coenzyme. No supplier on the platform currently has a testing score or a certificate-of-analysis link on file, so lot-specific purity and NADH content should be confirmed with the vendor.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide? No. It is a small-molecule quinolinium salt. It appears on a peptide marketplace because research suppliers list it alongside metabolic peptides, and because its target (NNMT) sits in the same NAD+ pathway that NAD+ and NMN research addresses.

What concentrations are used in cell culture? The 2018 characterization reported adipocyte lipogenesis and metabolite effects in cultured cells; investigators should run a concentration series and verify NNMT inhibition by measuring intracellular 1-methylnicotinamide, the direct product of the enzyme, rather than inferring it from a downstream phenotype.

Can I verify NADH content in the vial? Yes. NADH absorbs at 340 nm while NAD+ does not, so a simple UV spectrophotometric reading against a fresh NADH standard gives the reduced-cofactor content of a stored solution.

Related Pages on Peptides.SO

Background reading: the 5-Amino-1MQ NNMT inhibitor research profile, the NAD+ cellular energy and aging overview, and the NAD+ vs NMN comparison. Use the Stack Builder to model single-agent versus combined arms, and the reconstitution calculator for molar conversions.

Cited Research

Neelakantan H et al.. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PubMed 29155147

Dimet-Wiley A et al.. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. PubMed 35013352

Yang M et al.. NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer. 2024. PubMed 39067875

Covarrubias AJ et al.. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. PubMed 33353981

For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.